BIIB241122P195000
- 40.90
- 0.000.00%
Biogen Newsroom
Trump Picks Surgeon Makary to Head FDA, Rep. Dave Weldon to Lead CDC
Weekly Buzz: Nvidia Falls on Near Perfect Report, but Only For a Day
Market Climbs, Bitcoin Close to $100k | Live Stock
Goldman Sachs: Biogen Inc. (BIIB) Is A Top Growth Investor Stock
Biogen Price Target Lowered to $207 From $251 at Mizuho
Bitcoin Hits $99k, Thursday Market Whiplash Following Nvidia Price | Wall Street Today
Optimism Over Global Healthcare Sector Rises: Jefferies
Bitcoin Hits $98k, Nvidia Falls on Forward Guidance, Google Chrome Break-Up | Live Stock
Mizuho Maintains Outperform on Biogen, Lowers Price Target to $207
Biogen Analyst Ratings
Mizuho Securities Maintains Biogen(BIIB.US) With Buy Rating, Announces Target Price $207
European Commission Approves Samsung Bioepis, Biogen's Biosimilar Opuviz
Nvidia Forward Guidance Was Not Perfect, Market Flat | Wall Street Today
Biogen Gains Momentum With Positive Lupus Drug Results, Analyst Sees Modest Valuation Upside
Market Falls on Retail Results, Bitcoin Swells, All Eyes on Nvidia | Live Stock
Biogen On Pace For Lowest Close Since February 2013 -- Data Talk
Mizuho Securities Adjusts Price Target on Biogen to $207 From $251
Biogen Inc. (BIIB): Among the Best Genomics Stocks to Buy Right Now
Bitcoin Climbs to Fresh High, Market Shifts into Climb | Wall Street Today
Tuesday Market Falls, SMCI Flies, Big Box Retail Reports Mixed | Live Stock